Skip to content
The Nexus
HEALTHJun 1 · 12:00 UTCNBC NEWSKaitlin Sullivan

A personalized vaccine for melanoma cut the risk of cancer returning after five years

A personalized vaccine for melanoma reduced the risk of cancer recurrence after five years. The content also mentions a Johnson & Johnson COVID-19 vaccine being prepared for a clinical trial in Aurora, Colorado, in 2020.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Johnson & JohnsonorganizationAuroraplaceColoradoplacepersonalized vaccine for melanomatopicJohnson & Johnson COVID-19 vaccinetopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting